ORAI1 Deficiency (CRAC Channelopathy) — Disease Characterization Report

Autonomous discovery report. Evidence tiers indicated as: [Human clinical], [Model organism], [In vitro], [Computational/inferred]. Primary citations given as PMID.

Summary / Consensus Answer

ORAI1 Deficiency is an ultra-rare, autosomal-recessive primary immunodeficiency caused by loss-of-function mutations in ORAI1, the gene encoding the pore-forming subunit of the plasma-membrane Ca²⁺ release–activated Ca²⁺ (CRAC) channel. Loss of ORAI1 abolishes store-operated Ca²⁺ entry (SOCE), crippling the Ca²⁺/calcineurin/NFAT signaling axis. The disease — part of the broader entity "CRAC channelopathy" (which also includes STIM1 loss-of-function) — presents as a clinical tetrad: (1) a severe-combined-immunodeficiency (SCID)-like combined immunodeficiency with recurrent/severe infections, (2) autoimmunity/lymphoproliferation, (3) non-progressive congenital muscular hypotonia (myopathy), and (4) anhidrotic ectodermal dysplasia with defective sweating and dental enamel defects (amelogenesis imperfecta). Hematopoietic stem cell transplantation (HSCT) can cure the immunological disease but does not correct the non-hematopoietic (sweat gland, dental, muscle) manifestations.

Important nomenclature note: ORAI1 is a "two-faced" gene. Loss-of-function mutations (the subject of this report) cause the recessive immunodeficiency/CRAC channelopathy described here. Gain-of-function mutations in the same gene cause dominant tubular aggregate myopathy (TAM) and Stormorken syndrome — these are distinct diseases and are NOT "ORAI1 deficiency." They are mentioned only for contrast (26469693).

1. Disease Information

• Overview: A monogenic (Mendelian) inborn error of immunity in which absent CRAC-channel function eliminates SOCE in immune and non-immune cells. Because SOCE is the dominant Ca²⁺-influx pathway in T lymphocytes, sweat glands, and tooth-forming ameloblasts, the disorder is multisystem.
• Key identifiers:
• OMIM (phenotype): Immunodeficiency 9 (IMD9) #612782 ("combined immunodeficiency with anhidrotic ectodermal dysplasia").
• OMIM (gene): ORAI1 #610277.
• Orphanet: "CRAC channelopathy" / "Immunodeficiency due to a defect in CRAC channel" (Orphanet groups ORAI1 and STIM1 LOF together).
• Mondo: "immunodeficiency 9" / "combined immunodeficiency due to ORAI1 deficiency" (maps to OMIM #612782; a subtype under immunodeficiency-with-ectodermal-dysplasia); umbrella entity "CRAC channelopathy." (Exact MONDO accession should be verified against the current MONDO release; the OMIM #612782 cross-reference is the stable anchor.)
• ICD-10: D81.8 / D81.9 (combined immunodeficiencies, other/unspecified). ICD-11: 4A01.1Y (combined immunodeficiencies).
• MeSH: ORAI1 Protein (D000071140); Severe Combined Immunodeficiency (D016511) as related.
• HGNC: ORAI1 HGNC:25896; UniProt Q96D31; Ensembl ENSG00000276045 / ENSG00000152580.
• Synonyms / alternative names: Immunodeficiency 9; CRAC channelopathy (ORAI1-type); Combined immunodeficiency due to ORAI1 deficiency; ORAI1-CID; "Anhidrotic ectodermal dysplasia with immunodeficiency" (a distinct, ORAI1-specific form — noted by 29155098 as distinct from NEMO/IKBKG-related EDA-ID); SCID-like disease with SOCE defect. Older literature: "CRAC channel deficiency."
• Data source type: Information is disease-level and individual-patient (case-report/case-series) derived. Because <20–30 patients are reported worldwide, evidence comes from small kindreds, functional in-vitro studies of patient cells, and mouse models — not from population EHR or registry aggregates.

2. Etiology

Disease Causal Factors

• Primary cause = genetic. Biallelic (homozygous or compound heterozygous) loss-of-function variants in ORAI1 that abolish CRAC-channel function and SOCE [Human clinical; 16582901 29155098 26469693].
• No environmental, infectious, or toxic cause initiates the disease; environmental agents act only as downstream triggers of complications (opportunistic infections due to the immunodeficiency).

Risk Factors

• Genetic: The causal biallelic ORAI1 LOF genotype is necessary and sufficient. Consanguinity is a major risk factor because homozygous null alleles predominate in reported kindreds (recessive rare disease). Family history of an affected sib or of consanguineous union raises risk.
• Environmental / demographic: None established as causal. Heat exposure is a hazard (not a cause) because anhidrosis predisposes to hyperthermia/heat intolerance. Sex is not a risk factor (autosomal).

Protective Factors

• Genetic: Heterozygous carriers are clinically unaffected (recessive), although their T cells show partially reduced SOCE — a gene-dosage effect — demonstrating that ~50% channel function is protective [In vitro; 19075015]. Redundant Ca²⁺-entry contributions from paralogs ORAI2/ORAI3 and STIM2 may partially buffer some cell types (basis of variable non-immune expressivity) [Model organism/in vitro; 28294127].
• Environmental: Avoidance of heat, infection prophylaxis, and immune reconstitution are protective interventions (see §12–13), not innate protective factors.

Gene–Environment Interactions

• The genetic immunodeficiency sets susceptibility; pathogen exposure determines which infections manifest. Autoimmune flares may be triggered by infection due to loss of regulatory T-cell tolerance. No formal GxE quantitative data exist for this ultra-rare disease.

3. Phenotypes

Frequencies are qualitative (small n). HPO term suggestions included.

• Quality-of-life impact: High burden — recurrent hospitalizations for infection; lifelong infection prophylaxis; heat intolerance restricts activity/climate tolerance; dental restoration needs; muscle weakness affects motor milestones. Without immune reconstitution, early mortality is common. No formal EQ-5D/SF-36 data exist (ultra-rare).
• Evidence: 29155098 (subset deficits, enamel, anhidrosis, muscular dysplasia); 26469693 (tetrad); 28633876 (HLH as presenting manifestation of profound CID).

4. Genetic / Molecular Information

• Causal gene: ORAI1 (calcium release-activated calcium modulator 1), 12q24.31, HGNC:25896, OMIM gene #610277, UniProt Q96D31. Encodes a 301-aa tetraspanning (4-transmembrane) plasma-membrane protein; six ORAI1 subunits assemble into the hexameric CRAC-channel pore (concatemer functional analysis, 27806271; Drosophila Orai hexamer structure PDB 4HKR). Key pore/structural residues: E106 (Ca²⁺ selectivity filter, TM1), R91 (TM1); disease missense mutations (R91W, G98R, L194P) map to transmembrane/pore-proximal regions.
• Pathogenic variants (all LOF, biallelic; germline):
• c.271C>T, p.Arg91Trp (R91W) — first reported, homozygous; misfolds/mis-gates channel, abolishes CRAC current. Identified by combined SNP-array linkage + a Drosophila RNAi screen; WT ORAI1 re-expression rescued SOCE/I_CRAC in patient T cells, proving causality [PMID: 16582901].
• p.Val181SerfsX8 (frameshift), p.Leu194Pro (missense), p.Gly98Arg (missense) — homozygous; suppress ORAI1 protein expression and SOCE [PMID: 29155098].
• Additional reported nulls include a nonsense/premature-stop allele (A88Sfs-type) abrogating protein.
• Variant classes: missense (pore/TM), frameshift, nonsense/premature termination → all functionally loss-of-function (no/absent channel or non-conducting channel).
• ACMG classification: reported alleles are Pathogenic/Likely Pathogenic (functional SOCE assays = strong PS3 evidence; recessive segregation; absent SOCE).
• Allele frequency: Causal alleles are absent or ultrarare in gnomAD; ORAI1 is relatively tolerant to heterozygous LOF but biallelic LOF is nearly private to consanguineous kindreds.
• Somatic vs germline: Germline exclusively.
• Functional consequence: Loss of function (recessive). Contrast: gain-of-function ORAI1 (e.g., p.G98S, p.L138F, p.P245L, p.T184M) → constitutive SOCE → TAM/Stormorken (dominant) — different disease [PMID: 26469693].
• Modifier genes: Paralogous ORAI2, ORAI3 and ER sensors STIM1, STIM2 contribute to residual/tissue-specific SOCE and likely modify expressivity of non-immune features [PMID: 28294127].
• Epigenetic information: No disease-specific methylation/histone signature reported; not implicated.
• Chromosomal abnormalities: None — disease is due to point/small variants, not CNVs or aneuploidy.

5. Environmental Information

• Environmental factors: None causal. Pathogen exposure is the principal external factor determining infectious complications.
• Lifestyle factors: Not applicable to a Mendelian gene defect; heat/exercise exposure matters clinically due to anhidrosis (risk of hyperthermia).
• Infectious agents: Not a cause; opportunistic pathogens (CMV, EBV, Pneumocystis jirovecii, candida, other viruses/bacteria/fungi) act as downstream complications of the T-cell defect [PMID: 26469693; 26109647].

6. Mechanism / Pathophysiology

Causal chain (initiating lesion → clinical manifestation)

1. Biallelic LOF mutation in ORAI1 → loss/non-function of the CRAC-channel pore subunit in the plasma membrane. [Human clinical/in vitro; 16582901 29155098]
2. This results in abolished store-operated Ca²⁺ entry (SOCE): after antigen-receptor engagement, PLCγ → IP₃ depletes ER Ca²⁺ → STIM1 oligomerizes and senses depletion → but with no functional ORAI1, STIM1 cannot open a Ca²⁺ channel, so sustained cytosolic Ca²⁺ influx fails. [In vitro; 17572487]
3. Loss of the sustained Ca²⁺ signal leads to failure of calcineurin-mediated NFAT dephosphorylation → NFAT stays cytoplasmic → transcription of IL-2 and other cytokine/chemokine genes fails. [In vitro; 17572487]
4. In T cells this results in impaired proliferation, cytokine production, and effector differentiation despite normal lymphocyte numbers → SCID-like combined immunodeficiency → recurrent/opportunistic infections. [Human clinical; 26469693]
5. Branch (autoimmunity): SOCE loss results in strongly reduced invariant NKT and regulatory T (Treg) cells and altered γδ-T/NK subsets → breakdown of peripheral tolerance → autoimmune cytopenias, lymphoproliferation, HLH. [Human clinical; 29155098 28633876]
6. Branch (ectodermal — sweat glands): In eccrine sweat-gland epithelium, SOCE drives fluid/electrolyte secretion; ORAI1 loss leads to defective sweat secretion → anhidrosis → heat intolerance. [Inferred from tissue expression + phenotype; 26469693]
7. Branch (ectodermal — teeth): In ameloblasts/enamel cells, CRAC-channel (ORAI1/2/3 + STIM1/2) SOCE supplies the large Ca²⁺ flux needed for enamel mineralization — demonstrated directly in primary enamel cells (thapsigargin-evoked SOCE blocked by the CRAC inhibitor Synta-66), most abundant at the maturation stage; ORAI1 loss leads to hypomineralized enamel → amelogenesis imperfecta. [Model/in vitro + human; 26515404 28732182 28352661 30114531 29155098]
8. Branch (muscle): SOCE is required for skeletal-muscle Ca²⁺ homeostasis and development; when impaired, muscle is prone to early fatigue and myopathy, so ORAI1 loss leads to a non-progressive congenital myopathy / muscular hypotonia (a tissue-autonomous defect not corrected by HSCT). [Human clinical + model; 26469693 33262706]. Note the symmetry: GOF STIM1/ORAI1 → constitutive SOCE → tubular aggregate myopathy (31666234) — both excess and deficiency of SOCE injure muscle.

Category detail

• Molecular pathways: Store-operated Ca²⁺ entry / CRAC-channel pathway; Ca²⁺–calcineurin–NFAT signaling (Reactome R-HSA-2672351 "Stimuli-sensing / STIM-ORAI"; KEGG "Calcium signaling pathway" hsa04020). Downstream NFAT target-gene transcription.
• Cellular processes: T-cell activation, proliferation, cytokine secretion; immune synapse Ca²⁺ signaling; Treg/iNKT development; sweat-gland fluid secretion; ameloblast biomineralization; myocyte Ca²⁺ handling.
• Protein dysfunction: Loss of function — misfolded/mis-gated (missense) or absent (frameshift/nonsense) ORAI1 → non-conducting or absent CRAC channel. Not aggregation-related.
• Metabolic changes: No primary metabolic defect; secondary effects on Ca²⁺-dependent mitochondrial/energy signaling possible.
• Immune system involvement: Central — combined immunodeficiency plus autoimmunity (immunodysregulation), a hallmark "immunodeficiency-with-autoimmunity" pattern.
• Tissue damage mechanisms: Infection-driven tissue injury; autoimmune destruction of blood cells; HLH-associated inflammation.
• Biochemical abnormality: Ion-channel defect — loss of Ca²⁺-selective CRAC conductance (the defining biochemical lesion).
• Molecular profiling: Patient T cells/fibroblasts show absent SOCE on Ca²⁺ imaging and absent/greatly reduced CRAC current (I_CRAC) on patch-clamp; reduced ORAI1 protein by Western/flow [PMID: 29155098]. No large transcriptomic/proteomic/metabolomic disease atlases exist (ultra-rare).
• Functional genomics: Orai1 and Stim1/2 conditional-knockout mice recapitulate SOCE loss and immune defects, confirming causality [Model organism; 26109647].

Suggested ontology terms

• GO (BP): GO:0002115 (store-operated calcium entry), GO:0070588 (calcium ion transmembrane transport), GO:0033173 (calcineurin-NFAT signaling cascade), GO:0042110 (T cell activation).
• GO (MF): GO:0015279 (store-operated calcium channel activity).
• GO (CC): GO:0005886 (plasma membrane), GO:0034704 (calcium channel complex).
• CL: CL:0000084 (T cell), CL:0000815 (regulatory T cell), CL:0000921 (NKT cell), CL:0002064 (ameloblast/enamel-forming cell), CL:0000188 (skeletal muscle cell).

7. Anatomical Structures Affected

• Organ / system level:
• Primary: Immune system (thymus-derived T-cell compartment, lymphoid tissues) — UBERON:0002405 (immune system); integument/skin adnexa — eccrine sweat glands (UBERON:0001820); teeth/enamel organ (UBERON:0001091 tooth; UBERON:0007375 enamel); skeletal muscle (UBERON:0001134).
• Secondary: Blood (autoimmune cytopenias, UBERON:0000178); spleen/liver/lymph nodes (lymphoproliferation); lungs/GI (site of recurrent infection).
• Body systems: Immune, integumentary, musculoskeletal, hematologic, dental/craniofacial.
• Tissue / cell level:
• Epithelial: sweat-gland secretory epithelium; ameloblasts (enamel epithelium).
• Immune: T lymphocytes (esp. Treg, iNKT, γδ-T), NK cells.
• Muscle: skeletal myofibers.
• Cell Ontology: CL:0000084, CL:0000815, CL:0000921, CL:0002064, CL:0000188, CL:0000623 (NK cell).
• Subcellular level: Plasma membrane (site of the ORAI1/CRAC channel) and endoplasmic/sarcoplasmic reticulum (STIM1 sensor). GO-CC: GO:0005886 (plasma membrane), GO:0005783 (endoplasmic reticulum), GO:0034704 (calcium channel complex).
• Localization / lateralization: Systemic and bilateral/symmetric (generalized anhidrosis, generalized enamel involvement, generalized hypotonia); not focal or lateralized.

8. Temporal Development

• Onset: Congenital / neonatal–infantile. Immunodeficiency typically presents in the first months of life with severe infection; muscular hypotonia and anhidrosis are congenital; enamel defects become apparent as teeth erupt (childhood). Onset pattern: early, chronic, with acute infectious/autoimmune exacerbations.
• Progression:
• Immunodeficiency: persistent/lifelong unless corrected by HSCT; punctuated by acute infections and autoimmune flares (HLH can be fulminant, 28633876).
• Muscular hypotonia: non-progressive (static).
• Anhidrosis & enamel defects: stable/lifelong, non-progressive.
• Course pattern: Chronic lifelong disease with episodic infectious/autoimmune crises superimposed.
• Remission: No spontaneous remission of the underlying channel defect. Treatment-induced immune remission follows successful HSCT (immune compartment), but ectodermal/muscle features persist because they are non-hematopoietic.
• Critical period: Infancy is the window of highest mortality and the optimal window for definitive immune therapy (early HSCT before severe infection/organ damage).

9. Inheritance and Population

• Epidemiology: Ultra-rare. Fewer than ~30 patients with CRAC channelopathy (ORAI1 + STIM1 LOF combined) reported worldwide; ORAI1-LOF kindreds number a handful. Prevalence/incidence too low to estimate reliably (Orphanet: prevalence <1/1,000,000). No SEER/registry rates.
• Inheritance: Autosomal recessive (biallelic LOF). [PMID: 16582901, 29155098]
• Penetrance: Complete for the biallelic null genotype (all reported homozygotes affected); heterozygotes unaffected clinically though with subclinical partial SOCE reduction (gene-dosage) [PMID: 19075015].
• Expressivity: Variable across the tetrad — infection/immune severity and degree of muscle/ectodermal involvement differ between kindreds (possible paralog modifiers).
• Genetic anticipation: Not applicable (not a repeat-expansion disorder).
• Germline mosaicism: Not reported.
• Founder effects: Individual kindreds carry private homozygous alleles, typically in consanguineous families; no broad founder allele established.
• Consanguinity: Major — most reported cases arise from consanguineous unions (hallmark of rare recessive disease).
• Carrier frequency: Not established; biallelic pathogenic genotype essentially absent from population databases.
• Population demographics: Reported in multiple ethnicities (consanguineous kindreds from various regions); no strong ethnic predilection beyond consanguinity. Sex ratio ~1:1 (autosomal). Age distribution skews to infants/young children given early onset and historically high mortality.

10. Diagnostics

• Clinical / laboratory tests:
• Immunophenotyping (flow cytometry): Normal total T/B/NK counts (distinguishes from typical SCID) but reduced iNKT and Treg cells, altered γδ-T/NK subsets; poor in-vitro T-cell proliferation to mitogens/antigens [PMID: 29155098]. Immunoglobulins may be normal or with impaired specific antibody responses.
• Functional Ca²⁺ assay (diagnostic gold standard for the mechanism): Absent SOCE on single-cell Ca²⁺ imaging of patient T cells/fibroblasts; absent I_CRAC by patch-clamp [In vitro; 29155098 16582901].
• ORAI1 protein expression: reduced/absent by Western blot/flow.
• CBC (autoimmune cytopenias), Coombs test (AIHA), ferritin/triglycerides/sIL-2R (HLH work-up).
• Sweat testing (anhidrosis); dental exam (enamel hypoplasia/amelogenesis imperfecta); muscle exam/CK (usually normal-to-mildly abnormal; hypotonia clinical).
• Biomarkers: No circulating molecular biomarker; the functional SOCE defect and ORAI1 genotype are the definitive markers. LOINC codes apply to component tests (lymphocyte subsets, Ig levels).
• Imaging / electrophysiology: No pathognomonic imaging. EMG/muscle biopsy may show non-specific/mild myopathic changes; patch-clamp electrophysiology (research) demonstrates absent CRAC current.
• Biopsy/pathology: Sweat-gland biopsy shows structurally present but non-functional eccrine glands; tooth histology shows hypomineralized enamel.
• Genetic testing (definitive):
• Single-gene sequencing of ORAI1, or (preferred first-line today) primary-immunodeficiency gene panels or whole-exome sequencing (WES) / whole-genome sequencing (WGS) identifying biallelic ORAI1 LOF variants; confirm recessive segregation in parents [GTR/ClinVar].
• CMA/karyotype/FISH: not indicated (no CNVs). mtDNA/repeat-expansion testing: not applicable.
• Clinical criteria: No formal consensus criteria; diagnosis rests on the phenotypic tetrad + demonstration of absent SOCE + biallelic ORAI1 LOF.
• Differential diagnosis: Classical SCID (usually low T-cell counts — ORAI1 has normal counts); STIM1-LOF CRAC channelopathy (indistinguishable clinically — test STIM1); NEMO/IKBKG (EDA-ID) and NFKBIA anhidrotic ectodermal dysplasia with immunodeficiency (distinct — 29155098 notes ORAI1 form is distinct); ALPS and other IPEX-like immunodysregulation for the autoimmune component; primary HLH genes (PRF1, UNC13D) when HLH is the presentation (28633876).
• Screening: No newborn TREC screening detection (T-cell numbers normal, so ORAI1 deficiency is typically MISSED by TREC-based newborn SCID screening — an important caveat). Cascade carrier testing in consanguineous families and prenatal/preimplantation testing where the familial variant is known.

11. Outcome / Prognosis

• Survival / mortality: Historically poor without immune reconstitution — early death from overwhelming infection or fulminant autoimmunity/HLH is common in infancy/early childhood. With successful HSCT, immunological prognosis improves substantially.
• Morbidity / function: Even after immune cure, patients retain lifelong anhidrosis (heat intolerance), dental enamel disease, and muscular hypotonia because these are non-hematopoietic and not corrected by HSCT — a key prognostic point (26469693).
• Complications: Opportunistic/severe infections; autoimmune hemolytic anemia and thrombocytopenia; lymphoproliferation; HLH (can be presenting and life-threatening, 28633876); dental morbidity; hyperthermia episodes.
• Recovery potential: Immune compartment can be reconstituted (curative for infection/autoimmunity) via HSCT; non-immune features are permanent.
• Prognostic factors: Age at diagnosis, severity/organ damage from infection before treatment, occurrence of HLH, and success/timing of HSCT. No validated molecular prognostic biomarker beyond genotype.

12. Treatment

(No ORAI1-specific approved drug exists; management is that of combined immunodeficiency with immunodysregulation. NCIT terms suggested.)

• Definitive / curative:
• Allogeneic hematopoietic stem cell transplantation (HSCT) — corrects the hematopoietic/immune defect (donor immune cells have wild-type ORAI1). Does not correct sweat-gland, dental, or muscle disease. NCIT: C15431 (Hematopoietic Stem Cell Transplantation). [Supported by disease-mechanism logic + CID management standards; 26469693]
• Pharmacotherapy / supportive (symptom & complication management):
• Immunoglobulin replacement (IVIG/SCIG) for antibody insufficiency — NCIT: C578 (Immunoglobulin Therapy).
• Antimicrobial prophylaxis (e.g., trimethoprim-sulfamethoxazole against Pneumocystis; antifungal; antiviral) — NCIT: C15843 (Antibiotic Therapy).
• Immunosuppression for autoimmunity/HLH (corticosteroids, and HLH-directed therapy e.g., etoposide-based protocols when HLH occurs) — NCIT: C15370 (Immunosuppressive Therapy).
• Blood product/transfusion support for autoimmune cytopenias.
• Advanced / experimental: Gene therapy / gene correction of ORAI1 in autologous HSCs is a conceptual future approach (not clinically available). No approved RNA/targeted/immunotherapy specific to ORAI1 deficiency. (Note: CRAC-channel inhibitors, e.g., under development for autoimmune/inflammatory disease, are the opposite pharmacology and are contraindicated conceptually here.)
• Supportive / rehabilitative: Heat-avoidance and cooling strategies for anhidrosis; dental restoration/prosthodontics for enamel defects; physiotherapy for hypotonia; nutritional support.
• Pharmacogenomics: Not applicable specifically; standard HSCT-conditioning PGx (e.g., thiopurine/TPMT, busulfan monitoring) applies generically.
• Treatment algorithm: Early diagnosis → infection/autoimmune stabilization + prophylaxis + IVIG → definitive HSCT → lifelong management of non-immune (dental/sweat/muscle) features and heat precautions.

13. Prevention

• Primary prevention: No way to prevent the genetic lesion. Genetic counseling for consanguineous couples/known carriers; carrier screening, prenatal diagnosis, and preimplantation genetic testing (PGT) where the familial ORAI1 variant is known.
• Secondary prevention (early detection/treatment): Early clinical suspicion (infant with infections + anhidrosis + hypotonia + enamel defects) → SOCE functional assay + ORAI1 sequencing → early HSCT. Caveat: standard TREC newborn screening does not detect it (normal T-cell counts).
• Tertiary prevention (complication reduction): Infection prophylaxis, IVIG, vaccination caution (avoid live vaccines in immunodeficient patients), aggressive management of autoimmunity/HLH, heat-precautions, dental care.
• Immunization: Killed/inactivated vaccines per immunodeficiency guidelines; live vaccines contraindicated.
• Counseling: Autosomal-recessive counseling — 25% recurrence risk per pregnancy for carrier couples; cascade testing of relatives.
• Public-health/environmental: Not applicable (monogenic disease).

14. Other Species / Natural Disease

• Taxonomy / orthologs: ORAI1 is conserved across vertebrates. Mouse Orai1 (NCBI Gene ID 109305; MGI:1925542), rat Orai1, zebrafish, and a Drosophila ortholog (Orai) exist — the pathway was in part dissected in Drosophila RNAi screens.
• Natural disease in other species: A naturally occurring ORAI1-associated disorder in companion/wildlife species is not well documented in OMIA; the disease knowledge base is dominated by human patients and engineered animal models. (Not applicable / no strong natural-disease entry.)
• Comparative biology: SOCE and the STIM–ORAI mechanism are evolutionarily conserved from insects to mammals, making cross-species mechanistic inference valid. Mouse SOCE loss reproduces immune phenotypes, supporting conserved mechanism.
• Zoonotic potential / transmission: None (genetic, non-communicable).

15. Model Organisms

• Mouse (primary model; Mus musculus, NCBI Taxon 10090):
• Global Orai1 knockout: severe SOCE loss; reported perinatal lethality/reduced viability and small body size in some backgrounds, with immune defects — recapitulating the essentiality of CRAC channels. Surviving KO/knock-in models show impaired T-cell function.
• Orai1 R93W knock-in (mouse equivalent of human R91W) models the human SCID allele.
• Conditional/tissue-specific knockouts (e.g., Stim1/Stim2 double conditional; muscle-specific Orai1 KO) dissect cell-type roles — e.g., muscle-specific Orai1 deletion abolishes muscle SOCE (35939054), and Stim1/Stim2-deleted macrophages/DCs surprisingly retain many effector functions, showing lineage-specific SOCE dependence (26109647).
• Model types available: knockout, knock-in (point mutant), conditional/floxed, tissue-specific — via MGI/IMPC/KOMP.
• In vitro / cellular models: Patient-derived T cells and fibroblasts (absent SOCE/I_CRAC) are the definitive human cellular models [PMID: 29155098, 16582901]; heterologous ORAI1/STIM1 expression systems (HEK293) and concatenated tetramer constructs quantify gene-dosage effects of R91W [PMID: 19075015]. Ameloblast/enamel-cell models illustrate CRAC-dependent mineralization (30114531).
• Invertebrate: Drosophila Orai/Stim genetic screens established the pathway.
• Phenotype recapitulation: Mouse and patient-cell models faithfully reproduce the SOCE/immune defect; mouse models capture immune and muscle phenotypes well.
• Model limitations: Complete global Orai1 KO can be perinatally lethal in mice (more severe than the human hypomorphic/viable phenotype), and murine ectodermal (sweat/enamel) and autoimmune features may not fully phenocopy the human tetrad; paralog compensation differs between species.
• Resources: MGI (Orai1 MGI:1925542), IMPC/KOMP, IMSR for strain availability; ZFIN (zebrafish), FlyBase (Drosophila Orai).

Supported vs Refuted Hypotheses

• SUPPORTED: ORAI1 LOF → abolished SOCE → NFAT-signaling failure → combined immunodeficiency (16582901 17572487 26469693). ✔
• SUPPORTED: ORAI1 loss reduces iNKT/Treg cells → autoimmunity/immunodysregulation (29155098 28633876). ✔
• SUPPORTED: Multisystem (sweat gland, dental enamel, muscle) involvement reflects SOCE dependence of those tissues (26469693 30114531). ✔
• SUPPORTED: Recessive with dosage-dependent channel function (heterozygotes subclinical) (19075015). ✔
• CONTRAST/REFUTED as same disease: Gain-of-function ORAI1 is NOT "ORAI1 deficiency"; it causes dominant TAM/Stormorken (26469693). ✔ (kept distinct)

Limitations & Future Directions

• Ultra-rare disease: all clinical claims rest on small case series; no registry-level epidemiology, QoL, or survival statistics exist. Prevalence, penetrance-by-feature, and long-term HSCT outcomes are under-quantified.
• Some branch mechanisms (sweat gland, enamel) are inferred from tissue SOCE dependence and mouse data rather than proven in human tissue in vivo.
• Future: prospective natural-history registries; gene-correction/gene-therapy proof-of-concept; therapies for the non-hematopoietic (dental/sweat/muscle) features not addressed by HSCT.

Evidence key PMIDs: 16582901 (Feske 2006, first ORAI1 SCID mutation), 29155098 (novel recessive ORAI1 mutations, subset deficits), 26469693 (Lacruz & Feske review, disease definition & GOF contrast), 17572487 (SOCE–NFAT axis), 19075015 (heterozygous gene-dosage), 28633876 (HLH presentation), 30114531 (enamel/CRAC), 26109647 (innate-cell SOCE dependence, mouse), 35939054 (muscle-specific Orai1 KO), 29635109 (ion channelopathies of immune system review).